These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16896507)

  • 1. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Kiel DP; Reginster JY; Dore RK; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006; 17(11):1630-7. PubMed ID: 16896507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
    Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
    Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
    Ulivieri FM
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
    Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
    Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.
    Miller PD; Shergy WJ; Body JJ; Chen P; Rohe ME; Krege JH
    J Rheumatol; 2005 Aug; 32(8):1556-62. PubMed ID: 16078334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
    Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
    Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
    Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
    Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
    Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
    Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
    Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
    Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).
    Aloumanis K; Kapetanos G; Bartzis N; Drossinos V;
    BMC Musculoskelet Disord; 2015 Jun; 16():136. PubMed ID: 26044820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
    Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
    Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).
    Langdahl BL; Ljunggren Ö; Benhamou CL; Marin F; Kapetanos G; Kocjan T; Lespessailles E; Napoli N; Nikolic T; Petto H; Moll T; Lindh E
    Calcif Tissue Int; 2016 Sep; 99(3):259-71. PubMed ID: 27137783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
    J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
    Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
    Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.